Physician profile
Jonathon Fishman
NPI 1104813559
$91,929.38
in general payments reported to CMS, 2019-2025
45 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,216 · 2020: $2,240 · 2021: $2,766 · 2022: $2,642 · 2023: $16K · 2024: $32K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $10K · Travel and Lodging: $6,085 · Consulting Fee: $1,250 · Education: $72.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,262.66 |
| Food and Beverage | $10,394.26 |
| Travel and Lodging | $6,085.16 |
| Consulting Fee | $1,250.00 |
| Education | $72.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $40,470.02 | 2022-2025 | Dupixent |
| Genzyme Corporation | $31,512.26 | 2022-2025 | |
| Abbvie INC. | $4,620.58 | 2019-2025 | |
| Janssen Biotech, INC. | $1,798.85 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,786.49 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,767.15 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $1,717.36 | 2023-2025 | Ibsrela |
| Allergan, INC. | $1,490.53 | 2019 | |
| Pfizer INC. | $665.10 | 2019-2025 | |
| Gilead Sciences, INC. | $656.23 | 2019-2024 | |
| Lilly USA, LLC | $639.65 | 2023-2025 | Omvoh |
| Celgene Corporation | $579.92 | 2021-2024 | Zeposia |
| Organon LLC | $493.71 | 2021-2025 | Renflexis, Hadlima |
| Qol Medical, LLC | $447.18 | 2019-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $343.24 | 2019-2024 | Suflave, Sutab |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $277.47 | 2019-2023 | Linzess |
| Alfasigma USA, INC. | $251.53 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $245.53 | 2020-2023 | Rebyota |
| Celltrion USA INC. | $217.12 | 2024-2025 | Vegzelma, Zymfentra |
| Fresenius Kabi USA, LLC | $195.01 | 2023-2024 | Idacio |
| Amgen INC. | $170.34 | 2020-2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $163.55 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $157.04 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $134.36 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $131.66 | 2021-2024 | Dificid |
| Ucb, INC. | $110.44 | 2019-2020 | |
| Sandoz INC. | $108.61 | 2023-2024 | Hyrimoz |
| Daiichi Sankyo INC. | $101.57 | 2019-2024 | Injectafer |
| Echosens North America, INC. | $85.51 | 2022-2024 | Fibroscan |
| Madrigal Pharmaceuticals | $77.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Pentax of America, INC. | $63.18 | 2022 | |
| Intercept Pharmaceuticals, INC. | $55.82 | 2020-2025 | |
| Shionogi INC | $49.85 | 2019 | |
| Hologic Sales and Service, LLC | $47.33 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Nestle Healthcare Nutrition INC. | $46.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.12 | 2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $43.81 | 2022-2025 | Ultomiris |
| Novo Nordisk INC | $38.56 | 2024-2025 | Wegovy |
| Ethicon US, LLC | $33.27 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $23.20 | 2019 | |
| Endo Pharmaceuticals INC. | $20.66 | 2020 | |
| Medtronic, INC. | $17.27 | 2023 | Gi Genius |
| Ambu INC. | $16.02 | 2020 | |
| Olympus America INC. | $13.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,560.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.